E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib

Journal of Clinical Pathology

Volumn 63, Issue 8, 2010, Pages 737-740

  Bennour, Ayda ^a   Beaufils, Nathalie ^b   Sennana, Halima ^a   Meddeb, Balkis ^c   Saad, Ali ^a   Gabert, Jean ^b  

^a FARHAT HACHED HOSPITAL   (Tunisia)

^b HÔPITAL NORD   (France)

^c Hopital Aziza Othmana   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; COMPLEMENTARY DNA; IMATINIB;

ABDOMINAL DISCOMFORT; ADULT; ALLELE; ARTICLE; BONE MARROW; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DNA SEQUENCE; ELECTROPHORESIS; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE MUTATION; HUMAN; KARYOTYPE; LEUKOCYTOSIS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLENOMEGALY;

ADULT; ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MUTATION; PIPERAZINES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77955725237     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2010.078311     Document Type: Article

References (11)

1. Saglio G, Guerrasio A, Rosso C, et al. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 1990;76:1819-24.
2. Van Dongen JJ, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukaemia for detection of minimal residual disease. Report of the BIOMOED-1 Concerted Action: investigation of minimal residual disease in acute leukaemia. Leukemia 1999;13:1901-28.
3. Mascarenhas CC, Cunha AF, Miranda EC, et al. New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma 2009;50:1148-54.
4. Nicolini FE, Corm S, Lê QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospectve analysis from the French intergroup of CML (Fi(p)-LMC GROUP). Leukemia 2006;20:1061-6. (Pubitemid 43797298)
5. Verma D, Fava C, Kantarjian H, et al. Complexity of BCR - ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia. Am J Hematol 2009;84:256-7.
6. Popovici C, Charbonnier A, Gisserot O, et al. Y253H mutation appearing in a μ-BCR - ABL (e19a2) CML. Leuk Res 2008;32:361-2. (Pubitemid 351215527)
7. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR - ABL mutation status really matter? Blood 2009;114:5426-35.
8. Willis SG, Lange T, Demehri S, et al. High-sensitivity detection of BCR - ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005;106:2128-37. (Pubitemid 41291730)
9. Lee JJ, Kim HJ, Kim YJ, et al. Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR - ABL transcripts. Leukemia 2004;18:1539-40.
10. Mondal BC, Majumdar S, Dasgupta UB, et al. e19a2 BCR - ABL fusion transcript in typical chronic myeloid leukaemia: a report of two cases. J Clin Pathol 2006;59:1102-3. (Pubitemid 44570338)
11. Andrikovics H, Nahajevszky S, Szilvási A, et al. First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR - ABL transcripts. Hematol Oncol 2007;25:143-7. (Pubitemid 47507883)